Are there FDA-approved biosimilars for Cosentyx (secukinumab)?
As of the information provided here, there are no FDA-approved biosimilar alternatives to Cosentyx (secukinumab) listed.
What does “biosimilar approved by the FDA” mean in practice?
An FDA-approved biosimilar is a biologic product that the agency has reviewed and approved for use based on similarity to a specific reference product (in this case, Cosentyx/ secukinumab). The key point for patients and prescribers is that the FDA has explicitly authorized the product for clinical use—this is different from products that are under review, marketed outside the U.S., or offered as “interchangeable” only if the FDA has made that designation.
Could there be biosimilars for the same condition even if none are approved for Cosentyx?
Even if no Cosentyx biosimilar is FDA-approved, there may still be FDA-approved alternative biologics (not biosimilars of secukinumab) for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Those are different drugs with different biologic targets, not biosimilar copies of Cosentyx.
If you’re trying to switch from Cosentyx, what should you check?
If you’re seeking a lower-cost or more available option, the practical checks are whether there is (1) an FDA-approved secukinumab biosimilar, and (2) coverage or prior authorization options for any FDA-approved alternatives. Without an FDA-approved Cosentyx biosimilar, switching typically means moving to a different FDA-approved therapy rather than a biosimilar to Cosentyx.